Overview

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

Status:
Active, not recruiting
Trial end date:
2025-03-30
Target enrollment:
Participant gender:
Summary
Multicenter, open-label phase II trial assessing the efficacy of DS-8201a monotherapy in patients with metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
UNICANCER
Collaborator:
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Treatments:
Antibodies
Camptothecin
Immunoconjugates